Protagonist Therapeutics Inc (PTGX)

06:28 AM

Hussman Strategic Advisors Inc. Sells 21,000 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

06:28 AM

04:15 AM

How rising interest rates impact Protagonist Therapeutics Inc. stock2025 Performance Recap & High Accuracy Trade Alerts - newser.com

04:15 AM

03:55 AM

Can Protagonist Therapeutics Inc. hit a new high this monthQuarterly Earnings Summary & Real-Time Volume Surge Alerts - newser.com

03:55 AM

Nov 03, 2025

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - ACCESS Newswire

Nov 03, 2025

Nov 03, 2025

Protagonist (PTGX) to present 4 rusfertide presentations at ASH, including Phase 3 VERIFY - Stock Titan

Nov 03, 2025

Nov 03, 2025

Is Protagonist Therapeutics Inc. stock entering bullish territoryMarket Weekly Review & Step-by-Step Trade Execution Guides - newser.com

Nov 03, 2025

Nov 03, 2025

Protagonist Therapeutics Inc. stock chart pattern explainedMarket Risk Summary & Fast Moving Market Watchlists - newser.com

Nov 03, 2025

Nov 03, 2025

How Protagonist Therapeutics Inc. stock responds to policy changesJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com

Nov 03, 2025

Nov 03, 2025

Leerink Partnrs Issues Optimistic Forecast for PTGX Earnings - MarketBeat

Nov 03, 2025

Nov 02, 2025

How strong is Protagonist Therapeutics Inc. stock revenue growth2025 Momentum Check & Safe Capital Preservation Plans - newser.com

Nov 02, 2025

Nov 02, 2025

Price action breakdown for Protagonist Therapeutics Inc.July 2025 Recap & Free Fast Gain Swing Trade Alerts - newser.com

Nov 02, 2025

Nov 01, 2025

Is Protagonist Therapeutics Inc. stock a top pick in earnings season2025 Momentum Check & Weekly Return Optimization Alerts - newser.com

Nov 01, 2025

Nov 01, 2025

Protagonist Therapeutics, Inc. $PTGX is Moody Aldrich Partners LLC's 2nd Largest Position - MarketBeat

Nov 01, 2025

Oct 31, 2025

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Donaldsonville Chief

Oct 31, 2025

Oct 31, 2025

What is Wedbush's Estimate for PTGX FY2029 Earnings? - MarketBeat

Oct 31, 2025

Oct 31, 2025

Protagonist Therapeutics (PTGX) to Release Earnings on Thursday - MarketBeat

Oct 31, 2025

Oct 31, 2025

Will Protagonist Therapeutics Inc. stock benefit from commodity pricesProduct Launch & Daily Entry Point Alerts - newser.com

Oct 31, 2025

Oct 31, 2025

How Protagonist Therapeutics Inc. stock reacts to job market data2025 Market Outlook & Expert Curated Trade Setups - newser.com

Oct 31, 2025

Oct 30, 2025

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - Asbury Park Press

Oct 30, 2025

Oct 30, 2025

Protagonist Therapeutics (PTGX): Assessing Valuation After Breakthrough Phase 2b Results and Johnson & Johnson’s Phase 3 Launch - Sahm

Oct 30, 2025

Oct 30, 2025

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Oct 30, 2025

Oct 29, 2025

How to track smart money flows in Protagonist Therapeutics Inc.2025 Retail Activity & Risk Controlled Daily Trade Plans - newser.com

Oct 29, 2025

Oct 29, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $86.00 at Wedbush - MarketBeat

Oct 29, 2025

Oct 29, 2025

Protagonist Therapeutics (PTGX) Price Target Increased by 10.06% to 78.69 - Nasdaq

Oct 29, 2025

Oct 29, 2025

BTIG Research Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat

Oct 29, 2025

Oct 29, 2025

State of New Jersey Common Pension Fund D Sells 12,711 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Oct 29, 2025